Abstract
Abstract
Purpose
The incidence of salivary duct carcinoma (SDC) seems to be underestimated due to inaccurate classification. Further, the frequency of SDC patients with targeted therapy options according to current guidelines is unclear. Therefore, this study aimed at (a) describing the proportion of SDC among salivary gland carcinoma (SGC) before and after reclassification of cases initially classified as adenocarcinoma, not otherwise specified (ANOS); and (b) quantifying the frequency of SDC patients with targeted therapy options.
Methods
All patients with SDC or ANOS treated in a tertiary care center between 1996 and 2023 were identified. Histopathological diagnosis was verified for patients primarily diagnosed with SDC and reviewed for patients initially diagnosed with ANOS. Clinical data for SDC patients were retrieved from clinical charts. Immunohistochemical (IHC) androgen receptor (AR) and HER2 staining was performed.
Results
Among 46 SDC, 34 were primarily diagnosed as SDC and 12 had initially been classified as ANOS. The proportion of SDC among SGC was 12.1% and was rising when comparing the time periods 2000–2015 (7.1–11.5%) versus 2016–2023 (15.4–18.1%). Nuclear AR staining in > 70% of tumor cells was found in 56.8% and HER2 positivity (IHC 3 +) in 36.4% of cases. 70.5% of patients showed AR staining in > 70% of tumor cells and/or HER2 positivity and therefore at least one molecular target. 5-year overall and disease-free survival (DFS) were 62.8% and 41.0%. Multivariate Cox regression revealed positive resection margins (HR = 4.0, p = 0.03) as independent negative predictor for DFS.
Conclusions
The results suggest a rising SDC incidence and show that the extent of the AR and HER2 expression allows for targeted therapy in most SDC cases.
Funder
Universitätsklinikum Köln
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. WHO (2023) Head and neck tumours, WHO classification of tumours series,volume 9, 5th edn. International Agency for Research on Cancer, Lyon, p 2023
2. Roh JL, Lee JI, Choi SH, Nam SY, Kim SO, Cho KJ et al (2014) Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy. Oral Oncol 50(11):e64–e66
3. Stodulski D, Mikaszewski B, Majewska H, Kuczkowski J (2019) Parotid salivary duct carcinoma: a single institution’s 20-year experience. Eur Arch Otorhinolaryngol 276(7):2031–2038
4. Johnston ML, Huang SH, Waldron JN, Atenafu EG, Chan K, Cummings BJ et al (2016) Salivary duct carcinoma: treatment, outcomes, and patterns of failure. Head Neck 38(Suppl 1):E820–E826
5. Kusafuka K, Sato Y, Nakatani E, Baba S, Maeda M, Yamanegi K et al (2022) The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: multi-institutional retrospective analysis in Japan. Head Neck 44(6):1430–1441